Table of Contents
1. EXECUTIVE SUMMARY
1.1. Market Attractiveness Analysis
1.1.1. Global Pharmaceutical Quality Control Market, by Product
1.1.2. Global Pharmaceutical Quality Control Market, by Analysis Type
1.1.3. Global Pharmaceutical Quality Control Market, by Products Tested
1.1.4. Global Pharmaceutical Quality Control Market, by Region
2. MARKET INTRODUCTION
2.1. Definition
2.2. Scope of the Study
2.3. Market Structure
3. RESEARCH METHODOLOGY
3.1. Overview
3.2. Data Mining
3.3. Secondary Research
3.4. Primary Research
3.4.1. Primary Interviews and Information Gathering Process
3.4.2. Breakdown of Primary Respondents
3.5. Forecasting Techniques
3.6. Market Size Estimation
3.6.1. Bottom-Up Approach
3.6.2. Top-Down Approach
3.7. Data Triangulation
3.8. Validation
4. MARKET DYNAMICS
4.1. Introduction
4.2. Drivers
4.2.1. Growing pharmaceutical industry
4.2.2. Product launches
4.2.3. High research and development expenditures
4.3. Restraints
4.3.1. Presence of Ambiguous Regulatory Framework
4.4. Opportunities
4.5. COVID 19 Impact Analysis
4.5.1. Cost of Drugs and Raw Material
4.5.2. Research and Development Impact Analysis
4.5.3. Demand & Supply Gap Analysis
4.5.4. Opportunity Analysis
5. MARKET FACTOR ANALYSIS
5.1. Value Chain Analysis/Supply Chain Analysis
5.2. Porter’s Five Forces Model
5.2.1. Bargaining Power of Suppliers
5.2.2. Bargaining Power of Buyers
5.2.3. Threat of New Entrants
5.2.4. Threat of Substitutes
5.2.5. Intensity of Rivalry
6. GLOBAL PHARMACEUTICAL QUALITY CONTROL MARKET, BY PRODUCT
6.1. Overview
6.2. Consumables
6.3. Instruments
6.4. Services
7. GLOBAL PHARMACEUTICAL QUALITY CONTROL MARKET, BY ANALYSIS TYPE
7.1. Overview
7.2. Sterility Testing
7.2.1. Membrane Filtration
7.2.2. Direct Inoculation
7.2.3. Others
7.3. Bioburden Testing
7.3.1. Aerobic Count Testing
7.3.2. Anaerobic Count Testing
7.3.3. Spore Count Testing
7.3.4. Fungi/Mold Count Testing
7.4. Endotoxin Testing
7.4.1. In Vitro
7.4.2. Lal
7.4.3. Others
7.5. Stability Testing
7.6. Extractable & Leachable Testing
7.7. Raw Material Testing
7.8. Others
8. GLOBAL PHARMACEUTICAL QUALITY CONTROL MARKET, BY PRODUCTS TESTED
8.1. Overview
8.2. Vaccines
8.3. Plasma Product
8.4. Drugs
8.5. Others
9. GLOBAL PHARMACEUTICAL QUALITY CONTROL MARKET, BY REGION
9.1. Overview
9.2. Americas
9.2.1. North America
9.2.1.1. US
9.2.1.2. Canada
9.2.2. Latin America
9.3. Europe
9.3.1. Western Europe
9.3.1.1. Germany
9.3.1.2. France
9.3.1.3. UK
9.3.1.4. Italy
9.3.1.5. Spain
9.3.1.6. Rest of Western Europe
9.3.2. Eastern Europe
9.4. Asia-Pacific
9.4.1. China
9.4.2. India
9.4.3. Japan
9.4.4. Australia
9.4.5. South Korea
9.4.6. Rest of Asia-Pacific
9.5. Middle East & Africa
9.5.1. Middle East
9.5.2. Africa
10. COMPETITIVE LANDSCAPE
10.1. Introduction
10.2. Competitive Analysis
10.3. Market Share Analysis
10.4. Major Growth Strategy in the Global Pharmaceutical Quality Control Market
10.5. Competitive Benchmarking
10.6. Leading Player in terms of Number of Developments in Global Pharmaceutical Quality Control Market
10.7. Key Developments & Growth Strategies
10.7.1. New Product Launch
10.7.2. Merger & Acquisition
10.7.3. Joint Ventures
10.8. Major Players Financial Matrix
10.8.1. Sales & Operating Income 2019
10.8.2. Major Players R&D Expenditure 2019
11. COMPANY PROFILES
11.1. Merck KGaA
11.1.1. Company Overview
11.1.2. Financial Overview
11.1.3. Product Offered
11.1.4. Key Developments
11.1.5. SWOT Analysis
11.1.6. Key Strategies
11.2. bioMérieux SA
11.3. Charles River Laboratories International, Inc.
11.4. Sartorius AG
11.5. WuXi AppTec
11.6. Thermo Fisher Scientific, Inc.
11.7. SGS S.A.
11.8. Eurofins Scientific
11.9. Sartorius AG
11.10. Toxikon Corporation
11.11. Others
12. APPENDIX
12.1.1. Discussion Blueprint
12.1.2. Related Reports
NOTE:
This table of content is tentative and subject to change as the research progresses.
ï‚¡ In section 11, only the top 10 companies will be profiled. Each company will be profiled based on the Market Overview, Financials, and Product Portfolio, Business Strategies, and Recent Developments parameters.
ï‚¡ Please note: The financial details of the company cannot be provided if the information is not available in the public domain and or from reliable sources.
